An evaluation of memory services in Wales – preparing for disease modifying therapies

<h3></h3> The introduction of disease modifying therapies (DMTs) in Alzheimer’s disease (AD) will require a dramatic change in memory services across Wales. This study is the first to gather data from all seven health boards on the use of biomarkers. An early and accurate diagnosis is aided by advanced imaging, CSF biomarkers and collaboration between specialties. Memory services in all seven health boards in Wales were invited to take part in a semi-structured interview. Data was collected on CSF biomarker testing, imaging, access to a neurology opinion and preparedness for DMTs. Mental health departments managed all services with one exception where the medical department led and only this service had access to a neurology opinion in an MDT. Use of PET imaging was highly variable with one service requesting 60.2% of all FDG-PET scans in the past year. Only one service had a formal pathway for requesting CSF biomarkers of AD. This study highlights significant differences between memory services in Wales. It should be used to promote greater collaboration between services and help develop pathways for advanced diagnostic imaging and CSF testing. This would help ensure all patients have access to an early and accurate diagnosis and DMTs when available.